These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 16794493

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.
    Buléon M, Allard J, Jaafar A, Praddaude F, Dickson Z, Ranera MT, Pecher C, Girolami JP, Tack I.
    Am J Physiol Renal Physiol; 2008 May; 294(5):F1249-56. PubMed ID: 18367657
    [Abstract] [Full Text] [Related]

  • 23. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE, Ghai RD, Trapani AJ, Odorico LM, Dardik BN, De Lombaert S, Lappe RW, Fink CA.
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [Abstract] [Full Text] [Related]

  • 24. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
    Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH.
    J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
    [Abstract] [Full Text] [Related]

  • 25. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
    Hecker M, Blaukat A, Bara AT, Müller-Esterl W, Busse R.
    Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
    [Abstract] [Full Text] [Related]

  • 26. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N, Oike Y, Izumi-Nagai K, Koto T, Satofuka S, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Ishida S.
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [Abstract] [Full Text] [Related]

  • 27. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
    Burrell LM, Burchill L, Dean RG, Griggs K, Patel SK, Velkoska E.
    Exp Physiol; 2012 Apr; 97(4):477-85. PubMed ID: 22198016
    [Abstract] [Full Text] [Related]

  • 28. Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery.
    Miyamoto A, Murata S, Nishio A.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):365-70. PubMed ID: 12012022
    [Abstract] [Full Text] [Related]

  • 29. Neutral endopeptidase up-regulation in isolated human umbilical artery: involvement in desensitization of bradykinin-induced vasoconstrictor effects.
    Pelorosso FG, Halperin AV, Palma AM, Nowak W, Errasti AE, Rothlin RP.
    J Pharmacol Exp Ther; 2007 Feb; 320(2):713-20. PubMed ID: 17085545
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
    Arbin V, Claperon N, Fournié-Zaluski MC, Roques BP, Peyroux J.
    Br J Pharmacol; 2001 Jun; 133(4):495-502. PubMed ID: 11399666
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR.
    J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
    [Abstract] [Full Text] [Related]

  • 34. Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves.
    Helske S, Laine M, Kupari M, Lommi J, Turto H, Nurmi L, Tikkanen I, Werkkala K, Lindstedt KA, Kovanen PT.
    Eur Heart J; 2007 Aug; 28(15):1894-903. PubMed ID: 17507367
    [Abstract] [Full Text] [Related]

  • 35. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME.
    Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
    [Abstract] [Full Text] [Related]

  • 36. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
    Rousso P, Buclin T, Nussberger J, Décosterd LA, La Roche SD, Brunner-Ferber F, Brunner HR, Biollaz J.
    J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
    [Abstract] [Full Text] [Related]

  • 37. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
    Pfister M, Martin NE, Haskell LP, Barrett JS.
    J Clin Pharmacol; 2004 Jun; 44(6):621-31. PubMed ID: 15145970
    [Abstract] [Full Text] [Related]

  • 38. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S, Liu Y, Wang L, Meng QH.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [Abstract] [Full Text] [Related]

  • 39. Contribution of bradykinin to the cardiovascular effects of ramipril.
    Linz W, Wiemer G, Schölkens BA.
    J Cardiovasc Pharmacol; 1993 Sep; 22 Suppl 9():S1-8. PubMed ID: 7514234
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.
    Freise H, Palmes D, Spiegel HU.
    J Surg Res; 2006 Aug; 134(2):231-7. PubMed ID: 16513137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.